ASCELIA – AN ONCOLOGY-DEDICATED DRUG DEVELOPMENT COMPANY

ADVANCING
ORPHAN ONCOLOGY

TO IMPROVE THE LIFE OF PEOPLE
LIVING WITH CANCER
BY OFFERING BETTER TREATMENT OPTIONS

OUR STORY

Our Vision

2022-11-30 08:00:00

Our vision is to be a leader in identifying, developing and commercializing novel drugs that address unmet needs of people with rare cancer conditions.

Learn more about us:

Quarterly Report Q3-2022

Q3-2022 investor conference call

Ascelia Pharma company presentation May 2022

TOP STORIES

QUARTERLY REPORT Q3 2022: Successful completion of two out of three studies for regulatory submission

2022-11-04 08:00:00

Ascelia Pharma AB (publ) (ticker: ACE) today published its quarterly financial report for Q3 2022(January – September 2022), which is now available on the company’s website: https://www.ascelia.com/ir …

TOP STORIES

Ascelia Pharma expands its leadership team

2022.04.11

Ascelia Pharma AB (publ) (ticker: ACE) a biotech focused on improving the life of people living with rare cancer conditions, today announced that it has expanded its leadership team to include all lin …

TOP STORIES

New market research shows strong support for Orviglance

2022.03.29

New independent market research shows that 84% of healthcare professionals will likely use Orviglance® for magnetic resonance imaging (MRI) in patients with cancer in the liver and reduced kidney function.

Read more about the results:

Market Research Presentation

Upcoming Events

ABG Sundal Colliers Investor Day

Magnus Corfitzen will present Ascelia Pharma at ABG Sundal Colliers. The presentation will be livestreamed: https://cr.abgsc.com/

Fight Cancer Day 2023 with Redeye

Ascelia Pharma will present at Redeye Fight Cancer Day.

Full-Year report 2022

Report will be released at 08:00am CET and conference call at 10:00am CET

View all events

Latest News

Nomination Committee appointed for AGM 2023 in Ascelia Pharma AB

Ascelia Pharma AB (publ) (ticker: ACE) today announces that the Nomination Committee in preparation for the Annual General Meeting (AGM) on 4 May 2023 has been appointed In accordance with the instructions for the Nomination Committee in Ascelia Pharma, the Nomination Committee shall consist of four members representing the three largest shareholde …

ASCELIA PHARMA PRESENTS RESULTS OF ORVIGLANCE FOOD EFFECT STUDY AT RSNA 2022 SHOWING STRONG LIVER ENHANCEMENT BOTH WITH LIGHT MEAL AND IN FASTING CONDITION

30 November 2022: Ascelia Pharma AB (publ) – a biopharmaceutical company focused on improving the life of people living with rare cancer conditions – is presenting results from its Orviglance* Food Effect study at the RSNA conference 2022– 27 November – 1 December Chicago, Illinois). The study evaluates the effect of food intake on the […] …

QUARTERLY REPORT Q3 2022: Successful completion of two out of three studies for regulatory submission

Ascelia Pharma AB (publ) (ticker: ACE) today published its quarterly financial report for Q3 2022(January – September 2022), which is now available on the company’s website: https://www.ascelia.com/ir-media/financial-reports/ SIGNIFICANT EVENTS IN Q3 2022 Final results for the Hepatic Impairment Study marks the completion of the second study in the …

Presentations & Articles

ABGSC Investor Day

CEO Magnus Corfitzen presents at ABG Investor Day

HC Andersen – Oncology Seminar

Chief Executive Officer presents at HC Andersen Oncology Seminar

Erik Penser Bank – Company Day

Chief Executive Officer presents at Erik Pensers Company Day

INVESTOR

Shortcut to our latest Financial Reports

PEOPLE

Meet our CEO Magnus Corfitzen

Listen to Ascelia Pharma’s CEO Magnus Corfitzen and the vision and plans for the company